Chronic Liver Disease Market Summary

• The Chronic Liver Disease Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• The Chronic Liver Disease companies developing therapies include - Gilead Sciences, AbbVie, Novartis, Novo Nordisk, Bristol-Myers Squibb, GSK, Boehringer Ingelheim, Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Inventiva Pharma, Inipharm, Ochre Bio, Galectin Therapeutics, and others.

Chronic Liver Disease Market and Epidemiology Analysis

• The chronic Liver Disease Market is likely to observe a transformation due to increasing prevalence, improved diagnostic techniques, and changes in the treatment landscape, including advancements in the therapeutic portfolio.
• The Chronic Liver Disease treatment goal in Chronic Liver Disease is to stop the progression of the disease and complications where the principle of management is mainly underlying cause correction, portal hypertension management, and specific treatments for individual diseases. Chronic liver disease is burdensome as it lacks effective approved pharmacological therapies.
• The lack of Chronic Liver Disease drug approvals by authorized organizations hinders pharmaceutical market growth. Organ transplant is reserved for end stage liver disease patients and is quickly becoming a sizeable market in itself. 
• There is some optimism that new medications are likely to emerge during the forecast period. Semaglutide by Gilead Sciences, Inc. and Novo Nordisk A/S, Madrigal lead candidate, Resmetirom (formerly MGL-3196), along with various early and mid-staged clinical staged developmental candidates are currently shaping up the therapeutic landscape of Chronic Liver Disease addressing a vast array of unmet needs including combatting the underlying etiologies as well as complications associated.  

Factors Affecting the Chronic Liver Disease Market Growth

Rising Prevalence of Chronic Liver Diseases

The increasing global burden of chronic liver conditions such as Non-Alcoholic Fatty Liver Disease, hepatitis B, and hepatitis C is a major growth driver. Expanding patient populations, driven by metabolic disorders and infections, significantly boost demand for diagnostics and treatment, thereby accelerating overall Chronic Liver Disease market expansion.

Lifestyle Changes and Alcohol Consumption

Sedentary lifestyles, poor dietary habits, and rising alcohol intake are key contributors to chronic liver disorders. Increasing obesity and diabetes prevalence further elevate the risk of liver damage. These lifestyle-related factors are creating a sustained influx of patients, ensuring long-term growth opportunities for the Chronic Liver Disease therapeutics market.

Advancements in Treatment Options

Innovations in drug development, including biologics and targeted therapies, are transforming the treatment landscape. The emergence of disease-modifying therapies for liver fibrosis and NASH is improving patient outcomes. These advancements are encouraging higher adoption rates and expanding the commercial potential of the Chronic Liver Disease market.

Strong Pipeline and R&D Investments

Pharmaceutical companies are heavily investing in research and development to address unmet needs in liver diseases. A robust pipeline of late-stage candidates targeting fibrosis, inflammation, and metabolic pathways indicates future growth. Continuous innovation is expected to introduce more effective therapies and strengthen market competitiveness.

Improved Diagnostic Technologies

Advances in non-invasive diagnostic tools such as imaging and biomarker-based tests are enhancing early detection of liver diseases. Early diagnosis enables timely treatment and better disease management. This increased detection rate contributes to higher treatment uptake, ultimately supporting the expansion of the Chronic Liver Disease market.

Request a sample to unlock the CAGR for "Chronic Liver Disease Market Forecast"

DelveInsight’s “Chronic Liver Disease – Market Insights, Epidemiology, and Market Forecast – 2034” comprehensively analyzes the Chronic Liver Disease market, including market insights, market forecasts, drug uptakes, and drug penetration.

The chronic Liver Disease Market report examines historical epidemiology data for diagnosed prevalent cases and projects the same for the forecast period. Chronic Liver Disease diagnosed cases are further segmented by severity and treatable cases. The report also offers an in-depth understanding of various aspects of the disease, including diagnosis algorithm, prescription patterns, physician perceptions on treatment, current and future market developments for the 7MM, including the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2020 to 2034.

We provide country-wise in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of the pipeline products supporting the clients in their decision-making process regarding their therapeutic portfolio.

In order to gauge the market’s overall potential and recognize business opportunities, the report discusses the existing Chronic Liver Disease treatment practices and highlights unmet medical needs. 

Chronic Liver Disease Understanding

Chronic Liver Disease Overview

Chronic Liver Disease (CLD) refers to the gradual deterioration of liver function over time due to conditions such as Non-Alcoholic Fatty Liver Disease, alcoholic liver disease, and viral hepatitis. It progresses through stages including inflammation, fibrosis, cirrhosis, and potentially liver failure, often remaining asymptomatic in early phases, making awareness crucial.

Chronic Liver Disease Diagnosis

Diagnosis of Chronic Liver Disease involves a combination of blood tests, imaging techniques, and sometimes liver biopsy. Non-invasive tools like ultrasound and elastography help assess liver stiffness and damage. Early detection remains challenging due to subtle symptoms, often resulting in diagnosis at advanced stages when complications have already developed.

Chronic Liver Disease Treatment

Treatment of Chronic Liver Disease depends on the underlying cause and disease stage. Management strategies include antiviral drugs for hepatitis, lifestyle modifications, and medications targeting fibrosis. In advanced cases such as Cirrhosis, liver transplantation may be required, highlighting the need for more effective disease-modifying therapies.

Chronic Liver Disease Epidemiology 

This section provides a glimpse of the Chronic Liver Disease epidemiology in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan. The Chronic Liver Disease Epidemiology section provides insights into historical, current, and forecasted trends of the Chronic Liver Disease patient pool segmented by age, gender, and risk factors. This part of the report also provides the diagnosed and treated patient pools, their trends, and assumptions undertaken.

Key Findings from Chronic Liver Disease Epidemiological Analyses and Forecast

• Chronic liver disease is a leading cause of mortality, particularly in developing regions, with a steadily increasing global prevalence.
• In developed countries, the most common causes include alcoholic liver disease, chronic viral hepatitis (hepatitis B and C), non-alcoholic fatty liver disease (NAFLD), and hemochromatosis.
• In the United States, around 4.5 million adults were affected by chronic liver disease and cirrhosis, representing approximately 1.8% of the adult population.
• Chronic liver disease and cirrhosis accounted for 41,473 deaths in the U.S., with a mortality rate of 12.8 deaths per 100,000 population.

Chronic Liver Disease Market Segmentation

The DelveInsight report provides a detailed outlook of the current and future market of Chronic Liver Disease, segmented by countries, by therapies, and by classes to emphasize the changing market dynamics during the forecast period. 

Chronic Liver Disease Market Size by Countries

The total Chronic Liver Disease market of Chronic Liver Disease is analyzed for individual countries (the United States Market, EU4 (Germany, France, Italy, and Spain) and the UK market, and Japan Market). Due to a high number of prevalent cases and higher cost of therapies, the United States captured a higher share of the Chronic Liver Disease market in 2022 and is expected to continue to dominate the Chronic Liver Disease market in the future with plausible early entries of emerging products.

Chronic Liver Disease Market Size by Therapies

The total Chronic Liver Disease market, historical and forecast, is segmented by therapies and drug classes. In the case of Chronic Liver Disease, the market consists of non-surgical treatments, medications, and surgical interventions. The diagnosis of Chronic Liver Disease depends upon the etiology and complications of the disease, wherein a liver biopsy can confirm the diagnosis of Chronic Liver Disease. In most Chronic Liver Disease patients, “etiologic therapy” aims to eliminate the disease’s causal agents. However, despite etiologic therapies, some patients with decompensated cirrhosis are at risk of additional disease development. Therefore, novel therapeutics are urgently needed to focus on critical stages in the intricate pathophysiological chain of decompensated cirrhosis. Pertaining to the above-mentioned, culminating to all the factors has led to greater interest by key pharmaceutical players such as Novo Nordisk A/S, Madrigal Pharmaceuticals, Axcella Therapeutics, 89bio, Inc., and others to develop newer therapies that can drive the treatment market in the future.

Chronic Liver Disease Market Recent Developments and Breakthroughs

• In August 2025, The U.S. Food and Drug Administration approved semaglutide (Wegovy) for treating Metabolic Dysfunction-Associated Steatohepatitis with fibrosis, marking a major advancement as the first GLP-1–based therapy targeting liver disease progression.
• In August 2025, Regulatory approval of semaglutide expanded treatment options for MASH patients with moderate-to-advanced liver scarring, highlighting the growing role of metabolic therapies in liver disease management.
• In December 2025, The FDA qualified AIM-NASH, the first AI-based tool for assessing liver histology in clinical trials, improving accuracy and accelerating drug development for chronic liver diseases.
• In June 2025, The European regulator recommended conditional approval of resmetirom (Rezdiffra), a first-in-class therapy for MASH, signaling a breakthrough in addressing fibrosis-related liver damage.
• In February 2026, Madrigal Pharmaceuticals confirmed continued progress of Rezdiffra as a leading approved therapy for MASH with fibrosis across major markets, strengthening commercialization prospects.
• In January 2026, Ongoing pipeline advancements and clinical developments in MASH therapies indicate strong future growth, with multiple innovative candidates targeting inflammation and fibrosis pathways..

Chronic Liver Disease Drug Analysis 

Chronic Liver Disease Emerging Drugs

While several late-staged and early-staged therapeutics are under development, the pharmaceutical product pipeline of Chronic Liver Disease is prolific. It includes leading pharma players in the pursuit of cracking the code in the protracted hepatology space.

Semaglutide: Novo Nordisk 

Semaglutide is a selective GLP-1 receptor agonist given once daily, subcutaneously, for the treatment of non-alcoholic steatohepatitis (NASH). Based on studies, the development of Semaglutide in NASH is very much on track. It is currently in Phase III of its clinical development with a promise for closer to a solution that can be a potential launch in the hepatology space during the forecast period. 

Resmetirom (formerly MGL-3196): Madrigal Pharmaceuticals

Madrigal’s main attraction was its lead NASH compound, MGL-3196, a once-daily pill for fatty liver disease in-licensed from Roche, Resmetirom (formerly MGL-3196), a Phase III molecule that is a first-in-class, oral, once-daily formulation to target F2 and F3, and F4 stage patients. The company plans to file subpart H-accelerated approval for sooner entry into the market. This filling will be done based on recently published results; later, it will be continued by full NDA submission. Resmetirom also has FTD, which will help shorten the filling period. If all goes as planned, Resmetirom can be a potential launch in the hepatology space during the forecast period.

Note: Detailed emerging therapies assessment will be provided in the final report.

Chronic Liver Disease Market Outlook

The management of patients with Chronic Liver Disease depends on the stage of the liver disease. Liver fibrosis and cirrhosis result from underlying conditions like NASH, ALD, CHB, CHC, and others which progress to a stage of severity that becomes chronic due to the lack of standard treatment. 

As per the guidelines from the American Liver Foundation, without any branded approvals, management of underlying comorbidity that is central to treating NASH and related fibrosis is of utmost importance. Various off-label therapies are used to manage Chronic Liver Disease complications, such as vitamin E (an antioxidant), insulin sensitizers (e.g., metformin, pioglitazone), anti-hyperlipidemic agents (e.g., gemfibrozil), pentoxifylline, and UDCA. 

According to DelveInsight, the Chronic Liver Disease market is expected to witness considerable changes in the 7MM during the study period 2020–2034.

Chronic Liver Disease Competitive Landscape

The Chronic Liver Disease competitive landscape is moderately consolidated and driven by continuous innovation and strong research Chronic Liver Disease pipelines report. Competition focuses on developing disease-modifying therapies, particularly for fibrosis and metabolic liver disorders. Increasing clinical trial activity, strategic collaborations, and the entry of emerging players are intensifying competition, while unmet medical needs continue to create opportunities for novel therapeutic approaches.

Key Chronic Liver Disease Companies

The Chronic Liver Disease companies developing therapies include -

• Gilead Sciences,
• AbbVie,
• Novartis,
• Novo Nordisk,
• Bristol-Myers Squibb,
• GSK,
• Boehringer Ingelheim,
• Madrigal Pharmaceuticals,
• Intercept Pharmaceuticals,
• Inventiva Pharma,
• Inipharm,
• Ochre Bio,
• Galectin Therapeutics, and others

Chronic Liver Disease Drugs Uptake

This section focuses on the sales uptake of potential drugs anticipated to be launched in the Chronic Liver Disease pipeline report between 2023 and 2034. It estimates the market penetration of the drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the market. 

Chronic Liver Disease Competitive Intelligence Analysis

We perform Chronic Liver Disease clinical trial analysis of the Chronic Liver Disease Market using various Competitive Intelligence tools, including SWOT analysis, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Chronic Liver Disease Pipeline Development Activities

The Chronic Liver Disease Pipeline report covers detailed information on collaborations, acquisition and merger, licensing, patent details, and other information for Chronic Liver Disease emerging therapies.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Chronic Liver Disease.

Chronic Liver Disease Market Access and Reimbursement

DelveInsight’s Chronic Liver Disease Market report provides a descriptive overview of the market access and reimbursement scenario of Chronic Liver Disease. This section includes a detailed analysis of the country-wise healthcare system for each therapy, illuminating the market access, reimbursement policies, and health technology assessments. 

Latest KOL Views on Chronic Liver Disease

To keep up with current market trends and fulfill gaps in secondary findings, we conduct interviews with KOLs and SMEs’ working in the Chronic Liver Disease domain. Their opinions understand and validate current and emerging treatment patterns or Chronic Liver Disease market trends. This will support the clients with potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs. 

Chronic Liver Disease: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, hospitals, etc., such as Chronic Liver Disease Foundation, American Liver Foundation, and others.

E.g., “People who stop drinking alcohol after being diagnosed with a problem see significant improvement within 6–12 months.”

“Out of problem drinkers, around 35% experience severe liver disease due to various factors that worsen, delay, or stop the progression of alcoholic liver disease.”

Note: Detailed assessment of KOLs Views will be provided in the full report on Chronic Liver Disease.

Scope of the Chronic Liver Disease Market Report 

• The Chronic Liver Disease market report covers the descriptive overview of Chronic Liver Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Chronic Liver Disease epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Liver Disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Chronic Liver Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The Chronic Liver Disease report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Liver Disease market

Chronic Liver Disease Market Report Highlights

• In the coming years, Chronic Liver Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The Chronic Liver Disease companies and academics are working to assess challenges and seek opportunities that could influence Chronic Liver Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Chronic Liver Disease. Launch of Chronic Liver Disease emerging therapies will significantly impact the Chronic Liver Disease market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Liver Disease
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic Liver Disease Market Report Insights

• Chronic Liver Patient Population
• Chronic Liver Disease Therapeutic Approaches
• Chronic Liver Disease Pipeline Analysis
• Chronic Liver Disease Market Size and Trends
• Chronic Liver Disease Market Opportunities
• Impact of Upcoming Chronic Liver Disease Therapies

Chronic Liver Disease Market Report Key Strengths

• 10 Years Chronic Liver Disease Market Forecast
• The 7MM Coverage
• Chronic Liver Disease Epidemiology Segmentation
• Chronic Liver Disease Key Cross Competition
• Highly Analyzed Chronic Liver Disease Market
• Chronic Liver Disease Drugs Uptake

Chronic Liver Disease Market Report Assessment

• Chronic Liver Disease Current Treatment Practices
• Chronic Liver Disease Unmet Needs
• Chronic Liver Disease Pipeline Product Profiles
• Chronic Liver Disease Market Attractiveness

 Key Questions Answered in the Chronic Liver Disease Market Report 

• What are the major Chronic Liver Disease key players in the Chronic Liver Disease treatment space?
• At what CAGR is the Chronic Liver Disease market expected to grow by 7MM during the forecast period (2023–2034)?
• How would the unmet needs of chronic liver disease affect the market dynamics and subsequent analysis of the associated trends?
• What are the Chronic Liver Disease risk, burden, and regional/ethnic differences of Chronic Liver Disease?
• Where will be the growth opportunities in the 7MM concerning the patient population with Chronic Liver Disease? 
• What are the current treatment guidelines for treating Chronic Liver Disease in the US, Europe, and Japan?
• What major factors drive the market growth in the Chronic Liver Disease space?
• What are the current challenges faced in Chronic Liver Disease drug development?